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Abstract
In the present paper, we used the North American Rheumatoid Arthritis Consortium data
provided for Genetic Analysis Workshop 15 Problem 2 to: 1) estimate the penetrances of PTPN22
and HLA-DRB1 and, 2) test the selected model of PTPN22 conditional on the rheumatoid factor
status. To achieve these aims, we used the marker association segregation chi-square method,
fitting simultaneously both genotype frequency and identical by descent distributions in a sample of
3690 White individuals from 604 nuclear families. A co-dominant model fitted the rs2476601
(R620W) single-nucleotide polymorphism (SNP) of the PTPN22 gene well, whereas a lack of fit for
all models was observed for the HLA-DRB1 locus. Testing genetic models of rheumatoid arthritis
that include the PTPN22 SNP in addition to the HLA-DRB1 locus did not affect the results, nor did
subgroup analysis of PTPN22 conditional on the rheumatoid factor status. In conclusion, PTPN22
R620W SNP is a risk factor for rheumatoid arthritis. The genetic architecture of the HLA-DRB1
locus is highly complex, and more elaborate modeling of this locus is required.
Background
The HLA locus, and in particular several alleles of HLA-
DRB1, have been associated with rheumatoid arthritis
(RA) and other autoimmune disorders [1,2]. The specific
alleles being implicated vary according to population.
Commonly reported set of alleles are DRB1*0101, 0102,
0401, 0404, 0405, 0408, and 1001 [2]. However, these
alleles are either associated with severe forms of RA, or are
weakly and sometime inconsistently associated with RA.
Moreover, variability in disease expression is observed in
individuals with the same HLA background, ranging from
some being severely affected to others being unaffected
[2]. Therefore, HLA-DRB1 does not alone explain the
genetic susceptibility to common forms of RA. In addition
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genome scans [1,3,4] and/or by candidate gene
approaches [1,5]. Among the non-HLA loci, PTPN22, a
gene encoding for protein tyrosine phosphatase non-
receptor 22, is considered a strong candidate [1]. Phos-
phatases are known to play a role in immune-cell home-
ostasis. Recently, a functional single-nucleotide
polymorphism (SNP) in PTPN22 gene (R620W allele in
rs2476601) was reported to be associated with RA [4,5].
However, neither HLA-DRB1 nor PTPN22 rs 2476601
individually fully explain the genetic contribution to RA,
nor they are necessary or sufficient for RA to be present in
a given individual. Moreover, the association to RA may
be specific to rheumatoid factor-positive RA patients, as
recently reported for another PTPN22 variant [6]. Because
there is strong evidence implicating these two genes in RA,
and because the effect of PTPN22 variants may be
restricted to rheumatoid factor-positive patients, the pur-
pose of our study is twofold: first, to estimate the genetic
model (including penetrances) associated with these two
genes in White nuclear families from the North American
Rheumatoid Arthritis Consortium (NARAC) data; and
second, to model PTPN22 susceptibility conditional on
the rheumatoid factor status in RA patients. In the present
paper, we report that a co-dominant model best fits the
PTPN22 data and that stratification based on rheumatoid




We used the NARAC data of Problem 2 of the Genetic
Analysis Workshop 15 (GAW15). For the present paper,
only the data from individuals labeled as "Caucasian",
and those with "unknown" ethnicity, were considered (n
= 3690). We pooled these two ethnic categories because
the majority of the NARAC sample was white and the
allele frequencies for the four HLA-DRB1 microsatellites
(d6S265, TNFA, D6S273, and D6S1629), as well as the
rs2476601 SNP for PTPN22, were not statistically differ-
ent in the "unknown" ethnicity group compared to the
one labeled as Caucasian. We selected a sib-pair design
approach, and only one sib-pair per nuclear family was
included in the analysis. We could not use the full sib-pair
data available with the selected analytic approach due to
the non-independence of the various sib-pairs within sib-
ships. In families with more than two affected sibs, the
sibs with the most complete data and the closest in age
were those kept for analysis. The remaining affected sibs,
half sibs, and unaffected sibs, were excluded from the
analysis. In the context of multigenerational pedigrees,
each generation was split into nuclear families. Parental
data were used to compute the penetrances. Using the
data provided through GAW15, we defined as an index
case the sib from each pair that had the most complete
data.
HLA-DRB1 allele classification and PTPN22 rs2476601 
allele labeling
Because the HLA-DRB1 alleles reported to be associated
with RA share an RAA motif at position 71–74, our classi-
fication of the HLA-DRB1 alleles is based on their amino
acid sequence at that position [7]. When allele sub-types
were not available, we assigned the allele according to
their frequencies (e.g., 01R alleles were considered as
*0101; individuals with HLA-DRB*14 alleles were ran-
domly assigned half to *1401 and half *1402). We
assigned the HLA-DRB1*0101, *0405, *0408, *1001,
*1402, and *16 as E1, *0401 and *0409 as E2, *0102,
*0404, *423, *12, and *1406 as E3, and the other alleles
as Ex. The alleles classified as Ex were considered as the
non-susceptibility alleles. For PTPN22, the susceptibility
allele of the R620W missense SNP (rs2476601) corre-
sponds to the minor allele T, whereas the common allele
is C.
Statistical analyses
Genetic models for HLA-DRB1 and PTPN22 genes in RA
were tested using the marker association segregation chi-
square (MASC) method [8]. Details of this approach have
been described elsewhere [7,8]. Briefly, the MASC method
is based on the idea of minimizing a sum of independent
chi-squares and testing the goodness-of-fit of various
models [8]. This approach estimates penetrances simulta-
neously using information on the marker association and
segregation with the disease. Thus, MASC uses the allelic
association information from the genotype distribution
among unrelated index cases, as well as the linkage infor-
mation, based on the proportion of siblings sharing 2, 1,
or 0 alleles identical by descent (IBD), from each index
case and its affected sib. To deal with potential IBD esti-
mation uncertainty, the probability of sharing 2, 1, or 0
alleles IBD was computed for flanking SNPs using MER-
LIN. Based on IBD estimation probability of equal or
more than 80% for individual SNP, no ambiguity in IBD
sharing information was detected. Because the MASC
approach at some point is conditioning on the IBD status,
it cannot accommodate analyses of large sibships due the
non-independence of the sib-pairs within sibships.
Nuclear families with the following three configurations
were included: affected sibs and unaffected parents,
affected sibs and one affected parent, and affected sibs and
affected parents. These corresponded to MASC labels of
C2, C4, and C6, respectively. The data was then stratified
according to these distributions (i.e., family, genotype,
and IBD distributions) using the information on both the
index cases and their relatives. The expected distributions
were then computed for each proposed model. These dis-
tributions were used to estimate the relative penetrance ofPage 2 of 5
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given genotype to the penetrance for the referent (i.e., the
higher-risk genotype). These estimations require knowl-
edge of the genotype frequencies in the general popula-
tion. These were estimated using the affected family-based
association method (AFBAC) [9]. This approach uses the
parental alleles not transmitted to the children, assuming
Hardy-Weinberg equilibrium. In the context of multiplex
ascertainment, such as in the current study, the average of
the parental alleles transmitted to both sibs is compared
to the AFBAC population of parental alleles never trans-
mitted to the affected sib-pair. In the framework of MASC,
the genetic model is good (i.e., explains the observed asso-
ciation and linkage data) when the expected and the
observed distributions do not differ significantly. There-
fore, a p-value > 0.05 will correspond to the acceptance of
the model, whereas a p-value < 0.05 implies that other fac-
tors not modeled are involved in the disease expression.
We first fitted the co-dominant model, i.e., the most gen-
eral model. To test whether the penetrance of the different
genotypes differ significantly, pairwise comparisons were
performed with the maximum likelihood ratio test. Since
the co-dominant model fitted well, we then tested if the
penetrance for the heterozygotes and the homozygotes
were equals (dominant vs. co-dominant, recessive vs. co-
dominant). Confidence intervals for all estimates were
computed using a bootstrap procedure.
Results and discussion
Lack of fit of IBD data for HLA-DRB1 (data not shown)
The estimated general population allele frequencies are
15%, 6%, 5%, and 74% for E1, E2, E3, and Ex, respectively.
These frequencies are similar to those of the population
recruited in France through the European Consortium on
Rheumatoid Arthritis [7]. However, the allele classifica-
tion used in our study was not exactly like the new classi-
fication validated by the European Consortium study
because of the lack of sub-typing for some alleles, in par-
ticular DRB1*11 and DRB1*13. In our study, all the
expected distributions related to HLA-DRB1 differed sig-
nificantly from the observed distributions (p = 0.002). In
particular, in C4 families (i.e., the sibs and one parent are
affected), 79% of Ex/Ex probands share one HLA-DRB1
allele IBD with their affected sibling, compared to the
expected proportion of 48%. Thus, this model does not
explain all the observations. Therefore, we could not
model epistasis analyzing HLA-DRB1 conditional on
PTPN22.
A co-dominant model fits IBD data for PTPN22
The estimated general population allele frequency for the
T allele is 5% (thus, 95% for C) (data not shown). Table 1
shows the expected and the observed distributions for the
family configurations, the genotypes, and the IBD shar-
ing. Compared to the distributions at the HLA-DRB1
locus, there are more missing genotype values for the
PTPN22 locus, in particular for parents. Moreover, deter-
mination of IBD is sometimes difficult due to the bi-allelic
nature of the rs2476601 marker (i.e., SNP). Table 2
Table 1: Expecteda (Exp.) and Observed (Obs.) family configurations, genotypes and stratified IBD distributions for PTPN22 
rs2476601
IBD distribution (%)
Genotype distribution (%) IBD = 2 IBD = 1 IBD = 0
Family configurationb Genotype Exp. Obs. Exp. Obs. Exp. Obs. Exp. Obs.
C2 TT 1 2 42 25 47 75 11 0
nf = 447 Obs. TC 24 24 34 25 50 48 16 27
nf = 449 Exp. CC 75 74 26 22 50 55 24 23
C4 TT 3 2 - 50 - 50 - 0
nf = 147 Obs. TC 31 32 33 22 50 61 17 17
nf = 144 Exp. CC 66 66 26 36 50 41 24 23
C6 TT 5 0 - - - - - -
nf = 10 Obs. TC 35 30 - 50 - 50 - 0
nf = 11 Exp. CC 60 70 - 0 - 50 - 50
aExpected distributions are given under the co-dominant model.
bFamily configurations: C2, sibs are affected; parents are unaffected; C4, sibs are affected; one parent is affected; C6, sibs and parents are affected;
nf, number of families.
-, not computed. Genotype distributions for which the sample size is ten or less, and IBD distributions for which the sample size is five or less are 
not include in the model.Page 3 of 5
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various models. Only the co-dominant model fits the
observed distributions. Estimated penetrances for the co-
dominant model are 0.54 and 0.20 for TC and CC respec-
tively, versus the fixed penetrance of 1 for TT. The domi-
nant model with an estimated penetrance of 0.20 for CC
compared to TC and TT combined was rejected, as well as
the recessive model with a penetrance of 0.17 for TC and
CC combined compared to TT. Confidence intervals on
the penetrances, based on a bootstrap approach, are pre-
sented. The p-values are 0.20, 0.02, and <0.0001 for the
co-dominant, dominant, and recessive models, respec-
tively. The global penetrance, i.e., the estimated pene-
trance for TT, is 0.37. In Table 2, coupling refers to the
probability of carrying the susceptibility allele knowing
the marker allele. In this table, we observe that the T allele
has a probability of 1, whereas the probability associated
with the C allele is much lower (0.07). This strongly sug-
gests that the susceptibility allele is T, i.e., the marker
allele, or that of a gene in very close linkage disequilib-
rium with the marker locus.
Testing the co-dominant model of PTPN22 R620W 
conditional on the rheumatoid factor status
Table 3 shows the penetrance and coupling associated to
PTPN22 stratified according to the rheumatoid factor (RF)
status of the index case. RF+ and RF- are defined by IgM RF
values >14 and ≤14, respectively. For this analysis, 3648
individuals had known RF status (3002 RF+ and 646 RF-)
from 596 families (489 RF+ and 107 RF-). For both RF+
and RF-, models fit with the observed distribution (p =
0.33 for RF+, and 0.23 for RF-). However, the difference
between the stratified and unstratified models was not sta-
tistically significant (χ2 = 2.816, df = 4, p = 0.589).
Conclusion
Our results support the role of SNP R620W of the PTPN22
gene in the risk of developing RA. None of the models
tested fitted the data for HLA-DRB1. This further reinforce
the conclusion of Tezenas du Montcel et al. [7] that classi-
fication of HLA-DRB1 alleles is complex, and that some
classification systems may not capture the complexity at
this locus. Alternatively, the lack of fit of the main models
tested for HLA-DRB1 may also suggest that epistasis is a
major part of the underlying genetic architecture for this
locus, i.e., effect of an interaction without measurable
main effects. Better understanding of the genetic architec-
ture of RA will be essential not only to identify additional
genes implicated in RA but also as a critical component to
an eventual translation of genetic research knowledge into
clinical benefits for patients.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Acknowledgements
France Gagnon is a Canadian Institutes of Health Research (CIHR) New 
Investigator and a Canada Research Chair (CRC). We thank Dr. Françoise 
Table 3: Penetrance and coupling associated with PTPN22 
stratified by rheumatoid factor (RF) status
Patient status
Genotype RF+ RF- Total sample
Penetrancea
TT 1 1 1
TC 0.55 0.34 0.52
CC 0.19 0.20 0.19
Coupling
T 0.96 0.99 0.97
C 0.07 0.13 0.07
-2*log likelihood 1677.152 367.36 2047.328
p-value 0.33 0.23 0.20
aThe global penetrance is set to 0.37 in all models. The reference 
genotype is TT.
Table 2: Penetrance and coupling associated with PTPN22 rs2476601
Genotype Co-dominant Dominant model Recessive model
Penetrancea
TT 1 1 1
TC 0.54 [0.42–0.75] 1 0.17 [0.13–0.22]
CC 0.20 [0.12–0.30] 0.20 [0.14–0.28] 0.17 [0.13–0.22]
Coupling
T 0.99 [0.54–1] 0.27 [0.15–0.43] 0.99 [0.96–1]
C 0.07 [0–0.13] 0.01 [0–0.02] 0.22 [0.19–0.28]
-2*log likelihood -2066.63 -2073.72 -2093.58
p-value 0.20 0.02 1.5 × 10-5
aThe reference genotype is TTPage 4 of 5
(page number not for citation purposes)
BMC Proceedings 2007, 1(Suppl 1):S14 http://www.biomedcentral.com/1753-6561/1/S1/S14Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Clerget-Darpoux for providing the MASC software and for helpful discus-
sions on the MASC method.
This article has been published as part of BMC Proceedings Volume 1 Sup-
plement 1, 2007: Genetic Analysis Workshop 15: Gene Expression Analysis 
and Approaches to Detecting Multiple Functional Loci. The full contents of 
the supplement are available online at http://www.biomedcentral.com/
1753-6561/1?issue=S1.
References
1. Dieudé P, Cornélis F: Genetic basis of rheumatoid arthritis.
Joint Bone Spine 2005, 72:520-526.
2. Zanelli E, Breedveld FC, de Vries RRP: HLA class II association
with rheumatoid arthritis: facts and interpretations.  Hum
Immunol 2000, 61:1254-1261.
3. Etzel CJ, Chen WV, Shepard N, Jawaheer D, Cornelis F, Seldin MF,
Gregersen PK, Amos CI, for the North American Rheumatoid Arthri-
tis Consortium: Genome-wide analysis for rheumatoid arthri-
tis.  Hum Genet 2006, 119:634-641.
4. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, Nath SK, Harley JB: The
PTPN22 C1858T functional polymorphism and autoimmune
diseases-a meta-analysis.  Rheumatology 2007, 46:49-56.
5. Carlton VEH, Hu X, Chokkalingam AP, Schrodi SJ, Brandon R, Alex-
ander HC, Chang M, Catanese JJ, Leong DU, Ardlie KG, Kastner DL,
Seldin MF, Criswell LA, Gregersen PK, Beasley E, Thomson G, Amos
CI, Begovich AB: PTPN22 genetic variation: evidence for multi-
ple variants associated with rheumatoid arthritis.  Am J Hum
Genet 2005, 77:567-581.
6. Harrison P, Pointon JJ, Farrar C, Brown MA, Wordsworth BP:
Effects of PTPN22 C1858T polymorphism on susceptibility
and clinical characteristics of British Caucasian rheumatoid
arthritis patients.  Rheumatology 2006, 45:1009-1011.
7. Tezenas du Montcel S, Michou L, Petit-Teixeira E, Osorio J, Lemaire
I, Lasbleiz S, Pierlot C, Quillet P, Bardin T, Prum B, Cornelis F, Cler-
get-Darpoux F: New classification of HLA-DRB1 alleles sup-
ports the shared epitope hypothesis of rheumatoid arthritis
susceptibility.  Arthritis Rheum 2005, 52:1063-1068.
8. Clerget-Darpoux F, Babron MC, Prum B, Lathrop GM, Deschamps I,
Hors J: A new method to test genetic models in HLA associ-
ated diseases: the MASC method.  Ann Hum Genet 1988,
52:247-258.
9. Thomson G: Mapping disease genes: family-based association
studies.  Am J Hum Genet 1995, 57:487-498.Page 5 of 5
(page number not for citation purposes)
